Cargando…

Circulating tumor cells in breast cancer

Over the past decade, technically reliable circulating tumor cell (CTC) detection methods allowed the collection of large datasets of CTC counts in cancer patients. These data can be used either as a dynamic prognostic biomarker or as tumor material for “liquid biopsy”. Breast cancer appears to be t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bidard, Francois-Clement, Proudhon, Charlotte, Pierga, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528978/ https://www.ncbi.nlm.nih.gov/pubmed/26809472 http://dx.doi.org/10.1016/j.molonc.2016.01.001

Ejemplares similares

Circulating Tumor Cells in Early Breast Cancer
por: Thery, Laura, et al.
Publicado: (2019)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
por: Bidard, François-Clément, et al.
Publicado: (2012)

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients
por: Cabel, Luc, et al.
Publicado: (2019)

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
por: Bidard, François-Clément, et al.
Publicado: (2013)

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
por: Sabatier, Renaud, et al.
Publicado: (2021)

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer
por: Ligthart, Sjoerd T., et al.
Publicado: (2013)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
por: Cabel, Luc, et al.
Publicado: (2021)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
por: Vincent-Salomon, A, et al.
Publicado: (2008)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Cristall, Katrina, et al.
Publicado: (2021)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

International study on inter-reader variability for circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2014)

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
por: Chalumeau, Clelia, et al.
Publicado: (2022)

Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
por: Bourrier, Chantal, et al.
Publicado: (2020)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Bortolini Silveira, Amanda, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
por: Gerratana, Lorenzo, et al.
Publicado: (2022)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients
por: Franken, André, et al.
Publicado: (2021)

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
por: ALEMZADEH, EFFAT, et al.
Publicado: (2023)

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
por: Vuagnat, Perrine, et al.
Publicado: (2020)

Circulating tumor cells in breast cancer
por: Pukazhendhi, Geetha, et al.
Publicado: (2014)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
por: Chedid, Julien, et al.
Publicado: (2022)

Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
por: Addanki, Sridevi, et al.
Publicado: (2022)

Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery
por: Planeix, François, et al.
Publicado: (2015)

Quantifying HER-2 expression on circulating tumor cells by ACCEPT
por: Zeune, Leonie, et al.
Publicado: (2017)

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies
por: Tellez-Gabriel, Marta, et al.
Publicado: (2020)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

Minimal residual disease and circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer
por: Lisencu, Lorena Alexandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c8umpqiim0ol7te4cn6b4su7g0